TGTX
TG Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$55.99
−1.28%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
29.5x
EV/EBITDA
65.4x
Market Cap
$8.57B
MomentumView details →
1D Return
−1.28%
YTD Return
+87.55%
RSI (14)
58.4
ValuationView details →
P/E (Fwd)
29.5x
EV/EBITDA
65.4x
Market Cap
$8.57B
RSI (14)
58.4
MomentumView details →
1D Return
−1.28%
YTD Return
+87.55%
SummaryUpdated Jun 1, 2026
TG Therapeutics, Inc. (NASDAQ:TGTX) is a commercial-stage biopharmaceutical company founded in 1993 and headquartered in New York. The company focuses on developing and commercializing treatments for B-cell malignancies and autoimmune diseases. After decades of research and development, TG Therapeutics achieved its first major commercial milestone in December 2022 with FDA approval of <b>BRIUMVI</b>, a novel treatment for relapsing forms of multiple sclerosis. The company has since transitioned from a pure development-stage biotech to a commercial enterprise with significant revenue growth, generating over $329 million in 2024.
Similar companies
Latest newsMore news →
Deutsche Bank AG acquired a new stake of 235,481 shares in TG Therapeutics, Inc., valued at approximately $12.9 million, as disclosed in a Form 13F filing.12d agoTG Therapeutics announced its financial results for the second quarter of 2026, reporting total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million.32d ago